Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology and University of Tübingen, Auerbachstr. 112, 70376 Stuttgart, Germany.
Expert Rev Mol Diagn. 2013 May;13(4):349-65. doi: 10.1586/erm.13.26.
Estrogen-receptor positive breast cancer accounts for 75% of diagnosed breast cancers worldwide. There are currently two major options for adjuvant treatment: tamoxifen and aromatase inhibitors. Variability in metabolizing enzymes determines their pharmacokinetic profile, possibly affecting treatment response. Therefore, prediction of therapy outcome based on genotypes would enable a more personalized medicine approach, providing optimal therapy for each patient. In this review, the authors will discuss the current evidence on the most important metabolizing enzymes in endocrine therapy, with a special focus on CYP2D6 and its role in tamoxifen metabolism.
雌激素受体阳性乳腺癌占全球诊断乳腺癌的 75%。目前辅助治疗的主要选择有两种：他莫昔芬和芳香酶抑制剂。代谢酶的变异性决定了它们的药代动力学特征，可能影响治疗反应。因此，基于基因型预测治疗效果可以使治疗方法更加个体化，为每位患者提供最佳治疗。在这篇综述中，作者将讨论内分泌治疗中最重要的代谢酶的现有证据，特别关注 CYP2D6 及其在他莫昔芬代谢中的作用。
